Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Surgery Can be a Pain, But Opioids Not Always Best Elixir

Hand and Upper Limb Surgeon and Founder of OrthoNOW, Dr. Alejandro Badia, discusses new pain-control option Exparel from Pacira Pharmaceuticals; offers patient tips.


News provided by

OrthoNOW

Aug 13, 2019, 09:00 ET

Share this article

Share toX

Share this article

Share toX

Dr. Alejandro Badia
Dr. Alejandro Badia

MIAMI, Aug. 13, 2019 /PRNewswire-PRWeb/ -- Innovative pain management alternatives during and after surgery can significantly reduce the number of patients becoming chronic users – and abusers -- of opioid drugs, says noted orthopedic surgeon Alejandro Badia MD, founder and chief medical officer of the Badia Hand to Shoulder Center and OrthoNOW®, who has successfully paired standard anesthesia during surgery with a new, opioid-sparing analgesic.

Called EXPAREL®, from Pacira Pharmaceuticals, Inc., the non-narcotic drug is injected as a single dose at the site of the regional block (nerves that deaden extremity) and often directly into the surgical site as well to help produce postoperative pain relief. The medication incorporates technology that encapsulates it in liposomal particles, allowing release of the drug's pain-inhibiting properties for an extended period, Dr. Badia explains.

Today, we have many proven, opioid-sparing options, including minimally invasive operative techniques and pre- and post-surgical uses of advanced nerve-blocking agents and long-lasting local anesthetics like EXPAREL® to resolve both pain and inflammation.

Post this

"In a recent case with a patient Dr. Amy Chappell, a neurologist and prominent lifestyle medicine physician who sustained a massive rotator cuff tear requiring double row repair, a procedure that can be particularly painful, the patient only required an over-the-counter anti-inflammatory medication to mitigate discomfort following administration of EXPAREL® during surgery," says Dr. Badia. According to Dr. Chappell, "I never had pain after the surgery and the only real issue was having to wear the protective abuction pillow and sling"!

Another case involved Nick Mendez, the CEO of OrthoNOW®, an innovative orthopedic care delivery company, who underwent combined labral repair and insertion of the Regeneten® patch to his rotator cuff for a partial tear. Mr. Mendez stated, "I had slight discomfort but never pain that required me taking anything other than some Motrin and I was able to even continue working via my mobile phone the same day of the outpatient procedure".

The recent launch of a national education campaign underscores Dr. Badia's comments. The campaign encourages patients to discuss non-opioid options for pain management with their doctors prior to undergoing surgical procedures. Campaign sponsors cite data indicating that only a 10% reduction in the number of physician-written prescriptions for opioid drugs following surgery would mean 300,000 fewer patients becoming "persistent opioid users."

The National Institute on Drug Abuse reports that common prescription opioids like hydrocodone (Vicodin®), oxymorphone (Opana®), codeine and fentanyl are chemically similar to heroin. In fact, nearly 80% of Americans using heroin say they turned to the drug after initially misusing prescription opioids, the Institute states.

Dr. Badia points to a 2017 study in JAMA Surgery indicating that patients often receive prescriptions for a month's worth of opioid pills and that some 6% of them are still taking the drugs three months or longer after their procedures. Even more alarming, he says, is a March 2017 report from the Centers for Disease Control and Prevention, which found that as many as 13% of patients who received prescriptions for a week's supply of opioid drugs were still taking them a year later.

"Surgery, including orthopedic surgery which is sometimes associated with a higher level of postoperative pain, does not – and should not – require use of narcotics for pain management," Dr. Badia says. "Today, we have many proven, opioid-sparing options, including minimally invasive operative techniques and pre- and post-surgical uses of advanced nerve-blocking agents and long-lasting local anesthetics like EXPAREL® to resolve both pain and inflammation at the surgical site for at least the first 72 hours following surgery – when postoperative pain is the most acute."

Other opioid-sparing alternatives are explored in an educational report for pharmacists, entitled "Multimodal Analgesia in Orthopedic Surgery." The report advises that use of two or more medications "with different mechanisms of action" during surgery can have an "additive analgesic effect," obviating the need for opioids to quell postoperative pain.

Dr. Badia uses Enhanced Recovery After Surgery (ERAS) protocols as part of his practice to reduce reliance on opioids for pain management. ERAS are designed to improve a patient's overall surgical experience, including eliminating narcotic prescriptions after surgery.

A recent study published in the Journal of Neurosurgery: Spine determined that ERAS decreased patient opioid use one month postoperatively following elective spine and peripheral nerve surgeries, Dr. Badia says.

He emphasizes, however, that any equation for stemming the opioid epidemic must also include patient education.

As an example, he cites a 2018 Johns Hopkins Medicine study in Anesthesia & Analgesia where authors report only "a very small percentage" of patients are choosing to use common, readily available anti-inflammatory medications like ibuprofen or acetaminophen to avoid sole reliance on opioids for pain control. Patients surveyed for the study had undergone orthopedic surgery, specifically spine and joint surgery.

Other research has associated use of opioid-sparing anesthesia during surgery with lower morbidity and mortality rates, Dr. Badia says.

He offers patients these tips:

  • Before undergoing surgery, ask your doctor about opioid-sparing alternatives to manage pain.
  • Change your mindset. Narcotics are not the only option for maintaining comfort. Lower-cost, over-the-counter medications can prove just as effective, particularly if used in a combined, synergistic mode.
  • Follow prescriptions exactly. If you still experience pain when the prescription is ended, seek your doctor's advice about next steps.

Heed your doctor's or pharmacist's instructions regarding proper disposal of leftover opioid pills. Don't store them for "possible future use."

Bio: Alejandro Badia, MD, FACS, internationally renowned hand and upper-limb surgeon and founder of Badia Hand to Shoulder Center and OrthoNOW®, a walk-in orthopedic care clinic. He is a member the American Society for Surgery of the Hand, American Association for Hand Surgery and the American Academy of Orthopedic Surgeons. He is a specialist in treating all problems related to the hand and upper extremity including trauma, sports injury, joint reconstruction, nerve injuries and arthroscopic surgeries. http://www.OrthoNOWcare.com and http://www.drbadia.com.

SOURCE OrthoNOW

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.